PMID- 28744772
OWN - NLM
STAT- MEDLINE
DCOM- 20180628
LR  - 20240327
IS  - 1179-6901 (Electronic)
IS  - 1174-5886 (Print)
IS  - 1174-5886 (Linking)
VI  - 17
IP  - 3
DP  - 2017 Sep
TI  - Breakthrough Pain Management with Sublingual Fentanyl Tablets in Patients with 
      Cancer: Age Subgroup Analysis of a Multicenter Prospective Study.
PG  - 419-425
LID - 10.1007/s40268-017-0198-4 [doi]
AB  - INTRODUCTION: Breakthrough pain (BTP) management in patients with cancer is 
      challenging, especially in the elderly. However, no studies examining the 
      influence of age on BTP medication have been conducted. The aim of this work was 
      to investigate the effect of sublingual fentanyl tablets (SFTs) in terms of 
      efficacy, safety, and quality of life in two age categories. METHODS: We 
      performed age subgroup analyses (<65 and >/=65 years) from a recently completed 
      study conducted in Spain. Pain intensity (PI), onset of pain relief, frequency 
      and duration of BTP episodes, and adverse events (AEs) were assessed at 3, 7, 15, 
      and 30 days. Health-status instruments used were the Short Form 12, version 2 
      (SF-12v2) questionnaire, and the Hospital Anxiety and Depression Scale (HADS-A 
      and HADS-D). RESULTS: Twenty-six patients were aged <65 years and 54 were aged 
      >/=65 years. SF-12v2 scores did not enhance significantly from baseline. HADS 
      scores and PI decreased significantly at the end of the study, particularly in 
      younger patients (HADS-A: 19.05 vs. 14.41%; HADS-D: 21.35 vs. 18.57%; PI: 67.23 
      vs. 56.30%). Onset of analgesia began in 2-5 min in 63.3% of subjects aged 
      <65 years and in 36.4% of subjects aged >65 years. Most patients experienced one 
      to five daily episodes after 30 days, and <5% needed a treatment change. AEs were 
      less frequently reported in older individuals (20.5 vs. 36.4%). CONCLUSION: Age 
      subgroup analyses suggest that SFTs are an effective and safe treatment for the 
      management of BTP in cancer patients of all ages. SFTs may offer a well-tolerated 
      and efficient option to control cancer BTP in the elderly.
FAU - Guitart, Jordi
AU  - Guitart J
AD  - Department of Anesthesiology, Hospital Plato, C/Plato 21, 08006, Barcelona, 
      Spain. jordi.guitart@hospitalplato.com.
FAU - Vargas, Maria Isabel
AU  - Vargas MI
AD  - Department of Anesthesiology, Parc Sanitari Sant Joan de Deu, Barcelona, Spain.
FAU - De Sanctis, Vicente
AU  - De Sanctis V
AD  - Pain Unit, Department of Anesthesiology, Hospital Universitari Sagrat Cor, 
      Barcelona, Spain.
FAU - Folch, Jordi
AU  - Folch J
AD  - Department of Anesthesiology, Hospital Plato, C/Plato 21, 08006, Barcelona, 
      Spain.
FAU - Salazar, Rafael
AU  - Salazar R
AD  - Department of Anesthesiology, Hospital Comarcal d'Inca, Palma de Mallorca, Spain.
FAU - Fuentes, Jose
AU  - Fuentes J
AD  - Department of Anesthesiology, Pius Hospital de Valls, Tarragona, Spain.
FAU - Coma, Joan
AU  - Coma J
AD  - Department of Anesthesiology, Hospital General de l'Hospitalet, Barcelona, Spain.
FAU - Ferreras, Julia
AU  - Ferreras J
AD  - Pain Unit, Department of Anesthesiology, Hospital Residencia Sant Camil, 
      Barcelona, Spain.
FAU - Moya, Jordi
AU  - Moya J
AD  - Pain Unit, Department of Anesthesiology, Hospital Mateu Orfila, Menorca, Spain.
FAU - Tomas, Albert
AU  - Tomas A
AD  - Pain Unit, Department of Anesthesiology, Fundacio Hospital Sant Bernabe, 
      Barcelona, Spain.
FAU - Estivill, Pere
AU  - Estivill P
AD  - Department of Anesthesiology, Parc Sanitari Sant Joan de Deu, Barcelona, Spain.
FAU - Rodelas, Francisco
AU  - Rodelas F
AD  - Department of Anesthesiology, Hospital Comarcal d'Inca, Palma de Mallorca, Spain.
FAU - Jimenez, Antonio Javier
AU  - Jimenez AJ
AD  - Kyowa Kirin Farmaceutica SLU, Madrid, Spain.
FAU - Sanz, Almudena
AU  - Sanz A
AD  - Kyowa Kirin Farmaceutica SLU, Madrid, Spain.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - New Zealand
TA  - Drugs R D
JT  - Drugs in R&D
JID - 100883647
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Tablets)
RN  - UF599785JZ (Fentanyl)
SB  - IM
MH  - Administration, Sublingual
MH  - Age Factors
MH  - Aged
MH  - Analgesics, Opioid/*administration & dosage/adverse effects
MH  - Anxiety/epidemiology
MH  - Breakthrough Pain/*drug therapy/etiology
MH  - Cancer Pain/*drug therapy
MH  - Depression/epidemiology
MH  - Fentanyl/*administration & dosage/adverse effects
MH  - Humans
MH  - Middle Aged
MH  - Neoplasms/complications
MH  - Prospective Studies
MH  - Psychiatric Status Rating Scales
MH  - Quality of Life
MH  - Spain
MH  - Tablets
PMC - PMC5629138
COIS- CONFLICTS OF INTEREST: Jordi Guitart, MD declares he has no financial interest in 
      or financial conflict with the subject matter or materials discussed in the 
      manuscript. Maria Isabel Vargas declares he has no financial interest in or 
      financial conflict with the subject matter or materials discussed in the 
      manuscript. Vicente De Sanctis, MD declares he has no financial interest in or 
      financial conflict with the subject matter or materials discussed in the 
      manuscript. Jordi Folch declares he has no financial interest in or financial 
      conflict with the subject matter or materials discussed in the manuscript. Rafael 
      Salazar declares he has no financial interest in or financial conflict with the 
      subject matter or materials discussed in the manuscript. Jose Fuentes declares he 
      has no financial interest in or financial conflict with the subject matter or 
      materials discussed in the manuscript. Joan Coma declares he has no financial 
      interest in or financial conflict with the subject matter or materials discussed 
      in the manuscript. Julia Ferreras declares he has no financial interest in or 
      financial conflict with the subject matter or materials discussed in the 
      manuscript. Jordi Moya declares he has no financial interest in or financial 
      conflict with the subject matter or materials discussed in the manuscript. Albert 
      Tomas declares he has no financial interest in or financial conflict with the 
      subject matter or materials discussed in the manuscript. Pere Estivill declares 
      he has no financial interest in or financial conflict with the subject matter or 
      materials discussed in the manuscript. Francisco Rodelas declares he has no 
      financial interest in or financial conflict with the subject matter or materials 
      discussed in the manuscript. Antonio Javier Jimenez works at Medical Department 
      of Kyowa Kirin Farmaceutica, S.L.U. Almudena Sanz works at Medical Department of 
      Kyowa Kirin Farmaceutica, S.L.U. FUNDING: This study was funded by Kyowa Kirin 
      Farmaceutica, S.L.U.
EDAT- 2017/07/27 06:00
MHDA- 2018/06/29 06:00
PMCR- 2017/07/25
CRDT- 2017/07/27 06:00
PHST- 2017/07/27 06:00 [pubmed]
PHST- 2018/06/29 06:00 [medline]
PHST- 2017/07/27 06:00 [entrez]
PHST- 2017/07/25 00:00 [pmc-release]
AID - 10.1007/s40268-017-0198-4 [pii]
AID - 198 [pii]
AID - 10.1007/s40268-017-0198-4 [doi]
PST - ppublish
SO  - Drugs R D. 2017 Sep;17(3):419-425. doi: 10.1007/s40268-017-0198-4.